The association of combined oral contraceptives (OC) with higher blood pressure (BP) may be attenuated with pills with smaller doses of oestrogen. The effect of stopping OC on BP of patients with hypertension was not described to date. In a cohort study of patients with hypertension, we identified 72 women using OC among 2112 patients seen from 1989 to 2002. Stopping hormonal contraception was recommended to all. The main outcome measurement was BP change in women who stopped (n ¼ 44) and who did not stop (n ¼ 28) OC, adjusting for baseline BP and age. Odds ratio for having a reduction of at least 20 mmHg in systolic blood pressure (SBP) or 10 mmHg in diastolic blood pressure (DBP), adjusting for age, change in weight and prescription of BP-lowering drugs, were calculated. The mean follow-up time was 6.677.5 months. Participants who stopped and did not stop OC had similar baseline characteristics. The deltas of SBP (adjusted) were 15.172.6 mmHg in patients who stopped and 2.873.2 mmHg in patients who did not stop OC (P ¼ 0.004). The corresponding values for DBP were 10.471.8 and 2.772.2 mmHg (P ¼ 0.008), respectively. The odds ratio (adjusted) for having a decrease of at least 20 mmHg in SBP or 10 mmHg in DBP was 0.28 (95% CI 0.08-0.90) in patients who stopped OC. Stopping OC is an effective antihypertensive intervention in a clinical setting.
Introduction
Oral contraception remains as one of the contraceptive methods mostly used worldwide. In the United States, approximately 34.5 million women were using contraception in the last decade. 1 Oral contraceptives (OC) and tubal ligation correspond to 85% of the contraceptive methods used in Brazil. 2 In a population-based survey in Porto Alegre, 81.8% of the women in the reproductive age were using OC. 3 Despite several attempts to reducing the rate of undesirable effects of OC, many are unlikely to be fully eliminated. Higher blood pressure levels are among their usual adverse effects, 4, 5 and uncontrolled hypertension has been acknowledged as a relative contraindication for the use of combined OC. 6 Most studies documenting the association between hypertension and use of contraceptives involved compounds of first generation, with at least 50 mg of oestrogen. It was postulated that the incidence of hypertension would be lower if smaller doses of oestrogen were used. 7, 8 However, higher blood pressure (BP) levels were found even in patients using monophasic pills containing 30 mg of oestrogen. 9 In a cohort study, a two-fold increase in risk for hypertension was detected in current OC users, as compared to nonusers. 10 Recently, we found that among hypertensive patients referred to a hypertension clinic, those using OC presented the highest probability of having uncontrolled BP, mainly at the expense of diastolic pressure.
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Thus, the use of OC may worsen the prognosis of hypertensive women. An effective measure to lowering BP and consequent morbidity might be to substitute the contraceptive method, but as far as we know there are no studies showing the effectiveness of this measure. In this report, we demonstrate that stopping the use of OC is an effective antihypertensive intervention in a clinical setting.
Methods
Our data come from a prospectively planned cohort study of hypertensive patients that is on way since 1989 in the Hypertensive Outpatient Clinic of Hospital de Clinicas de Porto Alegre. A more detailed description and results of this study may be seen elsewhere. [11] [12] [13] [14] [15] In brief, the study was planned to investigate several aspects related to the diagnosis and management of hypertension in a clinical setting. The influence of hormonal contraceptives on the control of BP was one of the specific objectives established a priori. Patients enrolled in the original cohort represented the whole spectrum of patients with hypertension, since our outpatient clinic was open to the referral of patients with uncomplicated, resistant, and potentially secondary hypertension. In a register of 2112 patients seen from 1989 to 2002, 72 hypertensive women using combined OC were identified and constituted the sample for this study.
All participants were evaluated according to the protocol used in the main study, which included an extensive collection of data concerning medical history, physical examination, and laboratory testing.
BP was measured according to standard techniques at three consecutive visits. During each visit, BP was measured twice at 5-min interval. The mean of six BP measurements -usual BP -was used to diagnose and classify hypertension. Blood pressure diagnosis and classification for this analysis followed the recommendations from 7th report of the Joint National Committee (JNC). 16 Detailed questions were asked about the use of contraceptive methods (at the time of the visit or in the past) and method employed (Ogino-Knaus, condoms, pill, IUD, or diaphragm). Almost all women under oral contraception were using pills with 30 mg of oestrogen.
All patients using hormonal contraception were advised to change their method under the orientation of a gynaecologist, explaining the reasons for the measure. In the follow-up visits, the protocol included the questioning if the patient had stopped using the contraceptive. The groups for comparison consisted of patients who had stopped and patients who were still using them at the time of the follow-up visit.
The main outcome measure was the BP variation between the initial evaluation and the follow-up visit. A dummy variable was computed corresponding to the reduction of at least 20 mmHg in systolic pressure or 10 mmHg in diastolic pressure between the two visits.
The baseline prognostic characteristics were compared using the Student's t-test or the w 2 test when appropriate. The deltas of systolic and diastolic BP between baseline and follow-up visits were calculated and tested by a Student's t-test for independent samples. In a multivariate model, the deltas between the groups were adjusted for the baseline BP and age.
The rate of patients with improved prognosis (at least 20 mmHg decreasing in systolic pressure or 10 mmHg in diastolic pressure) in the two groups was evaluated using the w 2 test. Improved prognosis was also included as a dependent variable in a logistic regression model, controlling for age, antihypertensive drug prescription, and body weight variation. All statistical analyses were performed with SPSS version 10.0.
The project was approved by the Ethics Committee of our Institution. Since the participants were under usual medical care, a signed written consent was waived.
Results
The mean age of the patients was 37.776.2 years. The follow-up was 6.677.5 months (range ¼ 1-33 months). There was no difference in baseline characteristics between participants who stopped and did not stop the use of OC ( Table 1) . The antihypertensive treatment did not differ among groups. The reasons for not having stopped the use of OC were not systematically registered, but mostly comprised difficulties in getting the assistance of a gynaecologist or fear to use a less efficacious method.
The severity of hypertension was reclassified according to JNC 7 and did not differ among groups. In the group of patients who stopped combined OC, 9.1% were at the prehypertensive stage, 45.5% at stage 1, and 45.5% were classified at stage 2. Among those who did not stop using the contraceptive during the follow-up, there were 17.9% of patients classified as prehypertension, 25% classified as stage 1, and 57.1% as stage 2 hypertension (P ¼ 0.18 for comparison between groups). The antihypertensive drug and nondrug treatment did not differ among groups.
Systolic blood pressure (SBP) tended to be lower at follow-up visit in patients who stopped using OC, while the variation in diastolic pressure was not significantly different between groups (Table 2) . After adjustment for initial BP and age, the deltas of SBP and diastolic blood pressure (DBP) were significantly higher in the patients who stopped using OC (Table 2) .
There was a trend towards improved prognosis, defined as a reduction of at least 20 mmHg in SBP or 10 mmHg in DBP, in patients who stopped using the OC (Table 3) . After adjustment for age, variation in weight, and drug prescription at the initial visit, the association between stopping hormonal OC and improvement in prognosis turned significant (Figure 1 ). Controlling for other potential confounders, such as baseline BP, informed compliance with drug prescription and with adhesion to the hypocaloric diet did not change the estimates substantially.
Since the period of observation was too long, we looked at the association between OC suspension and BP changing in blocks or three periods of 4 years. Despite the wide confidence intervals, the associations were similar to the observed in the entire cohort. 
Discussion
The detailed recording of information in this cohort allowed to identifying a clinically significant BP lowering effect in hypertensive women who stopped using oestrogen-based hormonal contraceptives. We are not aware of other studies that have addressed this clinical question through this design. In the same cohort, we found that compliance with a hypocaloric diet and with the use of antihypertensive drugs was accompanied by a significant reduction in BP, but not compliance with the recommendation to increase physical activity and to follow a low sodium diet. 13 Compliance with the recommendation to stop using OC may be another effective antihypertensive measure. The magnitude of the effect, in average of 12.3 mmHg for SBP and 7.7 mmHg for DBP, is higher than the effect of other nondrug interventions accepted as effective. 16 The present findings were expected to a certain extent. The association between the use of OC and BP elevation has been repeatedly demonstrated.
11, [17] [18] [19] In the last Joint National Committee, JNC 7 report, it is emphasized that OC raise BP and that the risk of hypertension increases with length of use. They recommend that OC users should get their pressure levels checked regularly during the period when they are taking OC and that the onset of hypertension is a reason to consider other forms of contraception. 16 Most studies, however, have focused on the development of hypertension in women who were previously normotensive. There are only two studies 11,20 on patients with a previous diagnosis of hypertension, in whom a positive association was observed between BP and the use of OC, anticipating that the withdrawal of OC could be an appropriate measure to improve BP control in hypertensive women.
The relationship between higher BP and risk for cardiovascular and renal diseases was demonstrated in a large series of cohort studies, 21, 22 showing that risks are directly proportional to the usual BP levels of individuals. Pooling 61 cohort studies, with approximately 1 million of individuals (12.7 million person-years at risk), the investigators from the Prospective Studies Collaboration demonstrated that the incidence of stroke and coronary heart disease increased two-fold at each difference of 20 mmHg in usual SBP or 10 mmHg in usual DBP. 23 Accordingly, our findings show that stopping OC may lead to a reduction of almost 50% in cardiovascular risk.
The present study has some limitations. Despite the large size of the original cohort, just a few patients fulfilled the inclusion criteria. Owing to the relatively low statistical power, an alpha error may not be fully discarded (chance finding), but the differences in BP behaviour between participants who stopped and did not stop using OC seem to be consistent. Because of the non-experimental design, it cannot be ruled out that part of the BP lowering effect in patients who followed the recommendation of stopping the OC is due to other prognostic characteristics of these women. The most likely confounders, however, were controlled in the multivariate analysis and showed to be in the conservative side. This observation was made among a population attending to a hypertension clinic of a hospital offering secondary and tertiary care in Brazil, thus limiting generalizability to other populations.
In conclusion, we demonstrated that when women with hypertension treated in an outpatient setting stop using hormonal contraceptives, there is a clinically relevant reduction of BP and presumably an improvement in prognosis. The replacement of the contraceptive method is required in women with hypertension.
